

Synagis Prior Authorization Form Please fax the completed form to 1-888-399-0271. For questions or concerns, please call 1-800-488-0134.

Synagis® (palivizumab)

Patient information	1:			
Patient's (child's) name:		□M□F	Date:	
Gestational age at birth: W Patient's address:	/eeks Days Birth weight:	_lb/kg Current weight:lb/kg	DOB:	
City/State/ZIP:				
	Parent's r			
Primary insurance: Secondary insurance:	ID ID	No		
Secondary insurance		110		
Synagis criteria are b	ased on 2014 American Academy of P nat apply):	ediatrics guidelines. Medical au	thorization c	linical criteria
Infant/child's condition:				
 < 32 0/7 weeks GA weeks GA weeks GA weeks GA weeks GA weeks GA weeks after birth and who contains a second with a second will require and will require contains with pulled a second with a second with pulled weeks GA we well were gat we well and we well we well and weeks GA we well and weeks GA we well and weeks GA we well and we wel	≤12 months of age at start of RSV season) with Chronic Lung Disease of Prematurity defined who are ≤24 months with Chronic Lung Disease continue to require medical intervention (sup modynamically significant congenital heart e cardiac medical procedures, and/or mode monary abnormality or neuromuscular dis idered profoundly immunocompromised*	e of Prematurity defined as a requirent oplemental oxygen, chronic corticoster disease, those with cyanotic heart derate to severe pulmonary hyperter	nent > 21 percer roid or diuretic t disease receiv nsion	nt oxygen for at least 28 herapy) ing medication for heart
Documented diagnosis must be	Chronic lung disease: Infants and children ≤ 24 months who require at least 28 days of supplemental oxygen after birth and who continue to require medical intervention. Diagnosis: Mechanical ventilation: □ Yes □ No Days/Duration			
confirmed by the	Supplemental oxygen: □ Yes □ No Days/Duration			
individual's medical record and supplied	Steroids and/or diuretics: Yes No Days/Duration			
with the	Other:Days/Duration			
authorization request. Medical record documentation may include, but is not limited to: test reports, chart notes from clinician's	Cardiac (CHD): Infants and children ≤ 12 months with hemodynamically significant congenital heart disease: those with cyanotic heart disease receiving medication for heart failure and will require cardiac medical procedures and/or moderate to severe pulmonary hypertension. • With moderate to severe pulmonary hypertension – 747.83 • With cyanotic congenital heart disease – 746.9 • Receiving medication to control congestive heart failure – 779.89. List medications:			
office or hospital admission.	*Other conditions:			
uumission.				
	Diagnosis:			_
	Comments:			
Was a hospital/NICU dose giv	ren? Yes No Date administered:			
Drug claim to be submitted by ☐ Prescribing physician ☐ CVS Caremark ☐ Other		ldress:		Drug claim submitted to: ☐ Medical benefit ☐ Pharmacy benefit
lace of service:	☐ Member's home, administered by	□ Syna	gis clinic	
rescribing physician:				
			Fov:	
— 1114			_ rax:	
		Address:		
License No.:		DEA No.:	NPI No.: _	

Approved prior authorizations are contingent upon the eligibility of member at the time of service and the claim timely filing limits. Authorizations are not a guarantee of payment. Authorizations are based on medical necessity and are contingent upon eligibility and benefits.